Next Gen Diagnostics and Sheba Medical Center Announce Agreement for NGD to Sequence and Analyze Unique Collection of Highly Resistant Bacterial Infections

Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence- (WGS-) based detection of transmission and for the determination of bacterial susceptibility to antibiotics, and Sheba Medical Center, the largest medical complex in Israel and the Middle East, announce an agreement providing for the sequencing and analysis of a unique collection of highly antibiotic resistant bacterial strains, both for infection control and to better understand their complex mechanisms of resistance.

“NGD is committed to bringing its systems for the WGS-based detection of transmission of infection and prediction of drug resistance to Israel. Recent work (1) has shown that WGS-based detection of transmission can stop outbreaks, with benefits to patient welfare as well as financial savings to hospitals and insurers by reducing the extended stays caused by transmission of drug resistant infection,” noted Dr. Paul A. Rhodes, NGD Founder and CEO. “Israel’s and Sheba’s world class and uniquely integrated medical information systems are well-suited to evaluate the benefits of using of WGS to detect transmission, providing guidance to infection prevention teams charged with stopping outbreaks.”